Surgical treatments for men with benign prostatic enlargement: Cost effectiveness study

BMJ (Online)

Volumn 338, Issue 7704, 2009, Pages 1187-1190

  Armstrong, Nigel ^a   Vale, Luke ^b   Deverill, Mark ^d   Nabi, Ghulam ^c   McClinton, Samuel ^c   N'Dow, James ^c   Pickard, Robert ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIATHERMY; DIATHERMY VAPORIZATION; HOLMIUM LASER; HUMAN; LASER; MAJOR CLINICAL STUDY; MALE; MICROWAVE THERAPY; MINIMALLY INVASIVE PROCEDURE; MONTE CARLO METHOD; POTASSIUM TITANYL PHOSPHATE LASER; PRIORITY JOURNAL; PROBABILITY; PROSTATE HYPERTROPHY; QUALITY ADJUSTED LIFE YEAR; RELAPSE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CATHETER ABLATION; COST-BENEFIT ANALYSIS; HEALTH STATUS; HUMANS; LASER COAGULATION; MALE; MARKOV CHAINS; MICROWAVES; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATISM; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 67650077546     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b1288     Document Type: Article

References (30)

1. Boyle P, Robertson C, Mazzetta C, Keech M, Hobbs FD, Fourcade R, et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int 2003;92:409-14.
2. Emberton M, Andriole GL, De La Rosette J, Djavan B, Hoefner K, Vela NR, et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003;61:267-73.
3. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989;141:243-7.
4. Lourenco T, Pickard R, Vale L, Grant A, Fraser C, MacLennan G, et al. Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. BMJ 2008;337:a1662.
5. Lourenco T, Pickard R, Vale L, Grant A, Fraser C, MacLennan G et al. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. BMJ 2008;337:a449.
6. Blute M, Ackerman SJ, Rein AL, Beusterien K, Sullivan EM, Tanio CP et al. Cost effectiveness of microwave thermotherapy in patientswith benign prostatic hyperplasia: part II - results. Urology 2000;56:981-7.
7. DiSantostefano RL, Biddle AK, Lavelle JP. The long-term cost effectiveness of treatments for benign prostatic hyperplasia. Pharmacoeconomics 2006;24:171-91.
8. Howard K, Wortley S. Transurethral needle ablation (TUNA) for the treatment of benign prostatic hyperplasia. MSAC application 1014. Canberra: Medical Services Advisory Committee, 2002. www.msac.gov.au/internet/msac/ publishing.nsf/Content/1014-1.
9. National Institute for Health and Clinical Excellence. The guidelines manual 2007. www.nice.org.uk/aboutnice/howwework/ developingniceclinicalguidelines/clinicalguidelinedevelopmentmethods/ theguidelinesmanual2007/the-guidelines-manual-2007.jsp
10. Stafinski T, Menon D, Harris K, Maddern GG, Jhangri G. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia. Can Urol Assoc J 2008;2:124-34.
11. Tooher R, Sutherland P, Costello A, Gilling P, Rees G, Maddern G. A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia. J Urol 2004;171:1773-81.
12. Barry MJ, Williford WO, Yuchiao C, Machi M, Jones KM, Walker-Corkery E, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American urological association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995;154:1770-74.
13. Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004;172:2321-25.
14. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995;332:75-9.
15. Kok ET, McDonnell J, Stolk EA, Stoevelaar HJ, Busschbach JJV. The valuation of the international prostate symptom score (IPSS) for use in economic evaluations. Eur Urol 2002;42:491-97.
16. Ackerman SJ, Rein AL,BluteM, Beusterien K, Sullivan EM, Tanio CP, et al. Cost effectiveness of microwave thermotherapy in patientswith benign prostatic hyperplasia: part I - methods. Urology 2000;56:972-80.
17. NHS reference costs. NHS Trusts elective in-patient HRG data. London: Department of Health, 2005. www.dh.gov.uk/PolicyAndGuidance/ OrganisationPolicy/ FinanceAndPlanning/NHSReferenceCosts/fs/en.
18. Harding C, Robson W, Drinnan M, Sajeel M, Ramsden P, Griffiths C, et al. Predicting the outcome of prostatectomy using non-invasive bladder pressure and urine flow measurements. Eur Urol 2007;52:186-192.
19. American Urological Association. Guideline on the management of benign prostatic hyperplasia (BPH). Linthicum, MD: American Urological Association, 2003. www.auanet.org/guidelines/bph.cfm.
20. Madersbacher S, Lackner J, Brossner C, Rohlich M, Stancik I, Willinger M, et al. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. Eur Urol 2005;47:499-504.
21. Francisca EA, d'Ancona FC, Meuleman EJ, Debruyne FM, de la Rosette JJ. Sexual function following high energy microwave thermotherapy: results of a randomized controlled study comparing transurethral microwave thermotherapy to transurethral prostatic resection. J Urol 1999;161:486-90.
22. Lourenco T, Armstrong N, N'Dow J, Nabi G, Deverill M, Pickard R, et al. Systematic review and economicmodelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess 2008;12:1-516.
23. Seagroatt V. Mortality after prostatectomy: selection and surgical approach. Lancet 1995;346:1521-4.
24. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med 1995;332:75-9.
25. Briggs A. Handling uncertainty in economic evaluations and presenting the results. In:McGuire DM, McGuire A, eds. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press, 2001.
26. Norby B, Nielsen HV, Frimodt-Moller PC. Cost-effectiveness of new treatments for benign prostatic hyperplasia: results of a randomized trial comparing the short-term cost-effectiveness of transurethral interstitial laser coagulation of the prostate, transurethral microwave thermotherapy and standard transurethral resection or incision of the prostate. Scand J Urol Nephrol 2002;36:286-95.
27. Stovsky MD, Griffiths RI, Duff SB. A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia. J Urol 2006;176:1500-6.
28. Noble SM, Coast J, Brookes S, Neal DE, Abrams P, Peters TJ, Donovan JL. Transurethral prostate resection, non-contact laser therapy or conservative management in men with symptoms of benign prostatic enlargement? An economic evaluation. J Urol 2002;168:2476-82.
29. Horasanli K, SilayMS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 ml: a short-term prospective randomized trial. Urology 2008;71:247-51
30. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modelling. Med Decis Making 2004;24:207-27.